Sinovac Biotech Ltd. (NYSE Amex: SVA),is a biopharmaceutical company specializing in the research, development, manufacture and commercialization of vaccines, registered in Antigua and Bubda.

Sinovac has three subsidiaries: Sinovac Biotech Co., Ltd. (Sinovac Beijing). Tangshan Yian Bioengineering Co. Ltd., and Sinovac Biotech (Hong Kong) Ltd. Currently, Sinovac Beijing specializes in R&D, production and commercialization of human vaccines. Its mission is to supply vaccines to eliminate human diseases. Our aim is to provide Chinese children with international quality vaccines;and provide children in the world with vaccines made in China. Sinovac Beijing has commercialized inacitviated hepatitis A vaccine, combined hepatitis A and B vaccine, seasonal influenza vaccine. Globally, Sinovac Beijing is one of the few manufacturers who developed a pandemic influenza vaccine and received production license. Sinovac Beijing is the only company in China receiving this license. And currently, Sinovac Beijing is developing JE vaccine, human rabies vaccine, EV71 vaccines, conjugated pneumococcal vaccine, HIB vaccine, and meningitis vaccine, etc. Moreover, Sinovac is the first company in the world to have been granted permission to begin clinical trials for a vaccine to prevent SARS and successfully complete the phase I clinical trials.

Tangshan Yian is now focusing on developing, producing and commercializing veterinary vaccines. Tangshan Yian is developing an inactivated rabies vaccine.

All the production facilities of Sinovac Beijing and Tangshan Yian have the Good Manufacturing Practice (GMP) certificate granted by the State Food and Drug Administration (SFDA) of China.

Sinovac HK provides a platform for Sinovac’s products entering into international market through Hong Kong and seeking R&D collaborations in Hong Kong.

Sinovac has several strategic partners including Peking University, Institute of Laboratory Animal Science, National Institute for the Control of Pharmaceutical and Biological Products (NCPBP), National Institute for Viral Disease Control and Prevention, National Institute for Infectious Disease Control and Prevention, and Beijing Tiantan Biological Products Co., Ltd..

As the only member from developing countries, Sinovac Beijing joined the Influenza Vaccine Supply International Task Force (IVS) under International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) in 2007, which is a non-profit, non-governmental Organization (NGO) representing national industry associations and companies from both developed and developing countries. Sinovac is open and flexible to discuss any possible collaborative opportunity of international business and technology transfer.

For more details, please feel free to visit our English website at www.sinovac.com.

Address

Sinovac Biotech Ltd,
39 Shangdixi Road,
Haidian District
Beijing 100085, China
Tel: +86 10 82890088
Fax : +86 10 62966910